As explored in the first two papers in this series, decentralized clinical trials (DCTs) offer many benefits. For pharmaceutical companies, they make possible huge cost savings, efficiency improvements, accelerated time to regulatory approvals and faster time to market. Patients win, too, thanks to greater convenience and easier accessibility – especially if technologies bring research to remote and underserved populations and integrate clinical research with patients’ existing community health care providers. If decentralization is implemented thoughtfully, it can also help to improve the diversity of participants, reducing bias in clinical research.